AKT1 and neoplasm: However, prolonged drug use can significantly decrease the antitumor effect due to the mutation of EGFR or the activation of Met, which in turn triggers downstream RAS/RAF/MEK/ERK and ERBB3/PI3K/Akt signaling pathways, promoting tumor proliferation and reducing sensitivity to gefitinib.150, 151, 152, 153